Key Takeaways
- • THL Partners to acquire Celerion from H.I.G. Capital for $1.8 billion in an all-cash transaction expected to close by year-end 2026.
- • Celerion, a Lincoln, Nebraska-based clinical pharmacology and bioanalytical sciences provider founded in 2010, represents a strategic fit within THL's healthcare sector focus on middle-market growth companies.
- • THL's target investment range of $250 million to $2.5 billion in enterprise value aligns with Celerion's valuation, reflecting the firm's disciplined approach to healthcare platform acquisitions.
- • H.I.G. Capital's exit from Celerion marks a portfolio optimization move for the Miami-based firm, which maintains broader healthcare exposure across provider services, hospital operations, and life sciences verticals.
- • The transaction adds to healthcare and life sciences private equity activity in the clinical research outsourcing and drug development services segments.
Summary
THL Partners, the Boston-based private equity firm founded in 1974, has agreed to acquire Celerion from H.I.G. Capital for $1.8 billion. The transaction represents a significant deal in the healthcare and life sciences private equity market, targeting the clinical research services sector. Celerion, established in 2010 and headquartered in Lincoln, Nebraska, operates as a global provider of clinical pharmacology and bioanalytical sciences services—functions critical to pharmaceutical development and drug approval pathways.
THL Partners specializes in middle-market growth company investments, with a stated enterprise value target range of $250 million to $2.5 billion across select sectors including healthcare. This valuation structure positions Celerion squarely within THL's investment thesis. The firm's healthcare focus and expertise in scaling operational platforms make it a logical acquirer for a clinical services provider serving biopharmaceutical and contract research organization clients.
H.I.G. Capital, the Miami-headquartered investment firm founded in 1993, brings the asset to market following its ownership period. H.I.G. maintains a diversified portfolio approach across healthcare investments, including provider services, hospital and major medical facilities, and life sciences and pharmaceutical companies. The sale of Celerion reflects the firm's portfolio management and capital reallocation strategy, freeing capital for new deployment opportunities across its target sectors.
The transaction is anticipated to close before the end of 2026. The deal underscores sustained institutional interest in clinical research outsourcing platforms and bioanalytical services, particularly as biopharmaceutical companies maintain robust external relationships for preclinical and clinical trial support services.
THL Partners specializes in middle-market growth company investments, with a stated enterprise value target range of $250 million to $2.5 billion across select sectors including healthcare. This valuation structure positions Celerion squarely within THL's investment thesis. The firm's healthcare focus and expertise in scaling operational platforms make it a logical acquirer for a clinical services provider serving biopharmaceutical and contract research organization clients.
H.I.G. Capital, the Miami-headquartered investment firm founded in 1993, brings the asset to market following its ownership period. H.I.G. maintains a diversified portfolio approach across healthcare investments, including provider services, hospital and major medical facilities, and life sciences and pharmaceutical companies. The sale of Celerion reflects the firm's portfolio management and capital reallocation strategy, freeing capital for new deployment opportunities across its target sectors.
The transaction is anticipated to close before the end of 2026. The deal underscores sustained institutional interest in clinical research outsourcing platforms and bioanalytical services, particularly as biopharmaceutical companies maintain robust external relationships for preclinical and clinical trial support services.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.